Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2007

Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann B, Senn H-J

Abstract excerpt

The 10th St Gallen (Switzerland) expert consensus meeting in March 2007 refined and extended a target-oriented approach to adjuvant systemic therapy of early breast cancer. Target definition is inextricably intertwined with the availability of target-specific therapeutic agents. Since 2005, the presence of HER2 on the cell surface has been used as an effective target for trastuzumab much as steroid hormone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Chemotherapy, Adjuvant

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Risk Factors

Source

Identifiers

PMID: 17675394
DOI: 10.1093/annonc/mdm271

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.PMID 17675394Read ↗

Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An updateSemantic proximity Read ↗

Update on the Treatment of Early-Stage Triple-Negative Breast CancerSemantic proximity Read ↗

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.Semantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

Triple negative breast cancer: looking for the missing link between biology and treatments.Semantic proximity Read ↗

Breast cancer in Egypt: a review of disease presentation and detection strategies.Semantic proximity Read ↗

[Novel target therapies used in breast cancer management].Semantic proximity Read ↗

Progress in breast cancer: overview.Semantic proximity Read ↗

The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.Semantic proximity Read ↗

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read ↗

Hallmarks of triple negative breast cancer emerging at last?Semantic proximity Read ↗

Estrogen Regulated Genes Compel Apoptosis in Breast Cancer Cells, Whilst Stimulate Antitumor Activity in Peritumoral Immune Cells in a Janus-Faced MannerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.